Committed to the discovery, development and commercialization of oral direct-acting antiviral therapies.

HCV

Bemnifosbuvir + ruzasvir

In addition to COVID-19, bemnifosbuvir is also being developed in a Phase 2 clinical trial in combination with ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). As single agents, both bemnifosbuvir and ruzasvir have demonstrated potent pan-genotypic antiviral activity against HCV.

About Bemnifosbuvir + Ruzasvir

ATEA PHARMACEUTICALS

Combining innovative discoveries with development expertise to advance antivirals with the potential to transform treatments for patients with serious viral diseases.

Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies.

Advancing Oral Antiviral Therapies with Multibillion Dollar Market Opportunities

Hepatitis C (HCV)

HCV continues to be a healthcare crisis with number of new cases exceeding cures— global market in 2023 was approximately >$3 billion in net sales

  • ~2-4 million people in the US are estimated to have HCV
  • ~75% of diagnosed patients in the US are untreated

Innovative Therapies to Address Unmet Medical Needs

Hepatitis C (HCV)

Executing global Phase 2 combination trial for bemnifosbuvir + ruzasvir in HCV patients

  • 4Q’24: Final results expected from Phase 2 trial

Our science.

Leveraging our deep understanding of antiviral drug development, medicinal chemistry, biology, biochemistry and virology, we are discovering and developing novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Currently, we are focused on the development of orally-available direct-acting antiviral agents for the treatment of hepatitis C virus (HCV).

A network of hubs and spokes is suspended, representing the idea of a modular platform.

NEWS

Follow our progress.

Updates on bemnifosbuvir, other Atea product candidates and company news.

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the outcome of the global Phase 3 SUNRISE-3

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway

New Data Further Elucidates Bemnifosbuvir’s Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of RNA Viruses BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete SVR12 Results Expected 4Q’24 Bemnifosbuvir and Ruzasvir HCV Data Presented at EASL: Support Best-in-Class Potential with High Antiviral Potency, Low Risk of Drug Interaction, Short Treatment Duration and High Barrier